Emergent BioSolutions Q3 2025 Financial Results

Emergent BioSolutions Inc. reported its financial results for the third quarter of 2025, with total revenues of $231.1 million, surpassing the high end of its guidance by $21 million. The company achieved a net income of $51.2 million, with a net income margin of 22%. Adjusted EBITDA stood at $87.8 million, with an adjusted EBITDA margin of 38%. The company raised its full-year 2025 revenue and profitability guidance, reflecting confidence in its financial performance. Key highlights include strong sequential growth in naloxone revenue, primarily driven by NARCAN® Nasal Spray, and 11 medical countermeasures (MCM) contract modifications and product orders year-to-date. The company also highlighted its focus on long-term growth and shareholder value creation.